Stay updated with breaking news from Pharmaceutical Intelligence. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Laronidase is a recombinant enzyme commercialized by JCR Pharmaceuticals, with a leading Phase II program in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ).
Barzolvolimab is a monoclonal antibody commercialized by Celldex Therapeutics, with a leading Phase II program in Eosinophilic Esophagitis.
Eculizumab is under clinical development by Alexion Pharmaceuticals and currently in Phase II for Subarachnoid Hemorrhage.
MRT-2359 is under clinical development by Monte Rosa Therapeutics and currently in Phase II for Bladder Cancer.
CLN-617 is under clinical development by Cullinan Oncology and currently in Phase I for Head And Neck Cancer Squamous Cell Carcinoma.